- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00783926
Phase 1 Study of a H5N1 Influenza Vaccine (Reverse Genetic Reassortant)
October 7, 2015 updated by: Ology Bioservices
Double Blind, Multi-Center, Phase 1 Study of a Vero Cell-Derived, Whole Virus Clade 2 H5N1 Influenza Vaccine in Healthy Subjects Aged 18 to 45 Years
The objectives of this study are to assess the dose-related safety and immunogenicity of six different dose levels of inactivated, Vero cell-derived reverse genetic reassortant A/H5N1/Indonesia/05/2005 influenza vaccine in a healthy young adult population.
Subjects will receive 2 vaccinations (21 days apart) at the dose to which they were assigned.
Blood will be drawn from all subjects for serum antibody determination on Days 0, 21, 42 and 180.
Body temperature will be measured daily for 6 days following vaccination.
Injection site reactions and systemic reactions will be monitored throughout the entire 180 days of the study.
Safety data obtained at 7 days after the first vaccination for all dose levels in Cohort 1 will be reviewed by a Data Monitoring Committee and a recommendation will be obtained whether to proceed to the second vaccination of Cohort 1 and to the first vaccination of Cohort 2.
Study Overview
Status
Completed
Conditions
Study Type
Interventional
Enrollment (Actual)
422
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Kansas
-
Wichita, Kansas, United States, 67207
- Heartland Research Associates, LLC
-
-
Kentucky
-
Lexington, Kentucky, United States, 40509
- Central Kentucky Research Associates, Inc.
-
-
Missouri
-
Kansas City, Missouri, United States, 64114
- The Center for Pharmaceutical Research
-
-
New York
-
Rochester, New York, United States, 14609
- Rochester Clinical Research
-
-
Rhode Island
-
Warwick, Rhode Island, United States, 02886
- Omega Medical Research
-
-
Texas
-
Dallas, Texas, United States, 75234
- Research Across America
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 45 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
Subjects who
- Have an understanding of the study, agree to its provisions, and give written informed consent prior to study entry
- Are clinically healthy, as determined by the Investigator's clinical judgment through collection of medical history and performance of a physical examination
- Are physically and mentally capable of participating in the study
- Are willing to refrain from blood donation for the duration of Part A of the study (until Day 42 [= 21 days after the second vaccination])
- Agree to keep a daily record of symptoms for the duration of the study
- If female and capable of bearing children - have a negative urine pregnancy test result within 24 hours of the scheduled first vaccination and agree to employ adequate birth control measures for the duration of the study.
Exclusion Criteria:
Subjects will be excluded from participation in this study if they:
- Have a history of exposure to H5N1 influenza virus or a history of vaccination with an H5N1 influenza vaccine
- Are at potential occupational risk of contracting H5N1 influenza infection (e.g., poultry workers)
- Suffer from or have a history of a significant neurological, cardiovascular, pulmonary (including asthma), hepatic, rheumatic, autoimmune, hematological, metabolic or renal disorder
- Have a Body Mass Index > 35
- Have hypertension at screening that is graded as greater than Stage 1 (defined as a systolic pressure > 159 or diastolic pressure > 99) while seated and at rest (measurement shall be repeated twice before subject is excluded)
- Have clinically significant abnormal clinical laboratory values at screening as determined by the Investigator
- Have clinically significant electrocardiographic abnormalities at screening
- Test positive for HIV, HBcAb or HCV
- Suffer from any kind of immunodeficiency
- Suffer from a disease or were undergoing a form of treatment within 30 days of study entry or are currently undergoing a form of treatment that can be expected to influence immune response. Such treatment includes, but is not limited to, systemic or high dose inhaled (>800µg/day of beclomethasone dipropionate or equivalent) corticosteroids, radiation treatment or other immunosuppressive or cytotoxic drugs
- Have a history of severe allergic reactions (e.g. clinically severe urticaria, allergic rhinitis, asthma) or anaphylaxis (a medical emergency caused by an acute hypersensitivity reaction involving several organ systems including, but not limited to, cardio-respiratory signs with mucosal and/or skin changes (e.g. angioedema, etc) that presents as or rapidly progresses to a severe life-threatening reaction.
- Have a rash, dermatologic condition or tattoos which may interfere with injection site reaction rating
- Have received any blood products (e.g. a blood transfusion or immunoglobulins within 90 days of vaccination in this study
- Have donated one or more units of blood (approximately 450 mL) or plasma within 30 days of vaccination in this study
- Have received any live vaccine within 4 weeks or an inactivated vaccine or subunit vaccine within 2 weeks prior to vaccination in this study
- Have functional or surgical asplenia
- Have a positive urine drug screen (unless the subject is currently prescribed the drug detected by a licensed health care provider and the continued administration of the drug would not otherwise exclude the subject from participation)
- Have a known or suspected problem with alcohol or drug abuse
- Were administered an investigational drug within six weeks prior to study entry
- Are concurrently participating in a clinical study that includes the administration of an investigational product
- Are a member of the team conducting this study
- Are in a dependent relationship with the study Investigator or with a study team member. Dependent relationships include close relatives (i.e. children, partner/spouse, siblings, parents) as well as employees of the Investigator or site conducting the study
- If female: are pregnant or lactating
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cohort 1
60 subjects randomized in an equal number to six different vaccine doses
|
2 x 0.5 mL intramuscular injections 21 days apart (one of six different doses of hemagglutinin antigen without adjuvant)
|
Experimental: Cohort 2
Following review of safety data of Cohort 1, approximately 360 additional subjects randomized in an equal number to the six different vaccine doses
|
2 x 0.5 mL intramuscular injections 21 days apart (one of six different doses of hemagglutinin antigen without adjuvant)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of subjects with an antibody response to the vaccine strain associated with protection 21 days after the second vaccination
Time Frame: 42 days
|
42 days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Frequency and severity of systemic reactions and injection site reactions after the first and second vaccinations
Time Frame: 180 days
|
180 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Baxter BioScience Investigator, MD, Baxter Healthcare Corporation
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
July 1, 2008
Primary Completion (Actual)
February 1, 2009
Study Completion (Actual)
July 1, 2009
Study Registration Dates
First Submitted
October 31, 2008
First Submitted That Met QC Criteria
October 31, 2008
First Posted (Estimate)
November 2, 2008
Study Record Updates
Last Update Posted (Estimate)
October 9, 2015
Last Update Submitted That Met QC Criteria
October 7, 2015
Last Verified
July 1, 2009
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 810801
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Influenza
-
Novartis VaccinesCompletedInfluenza | Seasonal Influenza | Human Influenza | Influenza Due to Unspecified Influenza VirusBelgium
-
Gamaleya Research Institute of Epidemiology and...CompletedInfluenza A | Influenza A Virus Infection | Influenza Epidemic | Influenza H5N1Russian Federation
-
Vanderbilt University Medical CenterHuman Vaccines ProjectCompletedVaccine Reaction | Influenza | Influenza, Human | Influenza A | Influenza Type B | Influenza A H3N2 | Influenza A H1N1United States
-
National Institute of Allergy and Infectious Diseases...CompletedInfluenza Immunisation | Avian InfluenzaUnited States
-
National Institute of Allergy and Infectious Diseases...Completed
-
National Institute of Allergy and Infectious Diseases...Completed
-
National Institute of Allergy and Infectious Diseases...CompletedInfluenza Immunisation | Avian InfluenzaUnited States
-
National Institute of Allergy and Infectious Diseases...CompletedInfluenza | Influenza Immunisation | Avian InfluenzaUnited States
-
National Institute of Allergy and Infectious Diseases...CompletedInfluenza Immunisation | Avian InfluenzaUnited States
-
National Institute of Allergy and Infectious Diseases...National Institutes of Health (NIH)CompletedInfluenza AUnited States
Clinical Trials on H5N1 Influenza Vaccine, Whole virion, Vero cell-derived, Inactivated Influenza Vaccine, non-adjuvanted (reverse genetic reassortant/H5N1 hemagglutinin antigen)
-
Ology BioservicesCompleted
-
Ology BioservicesCompletedInfluenza, AvianAustralia, Finland, Singapore, Spain
-
Ology BioservicesCompleted
-
Ology BioservicesCompletedInfluenzaAustria, Belgium, Finland, Germany, Latvia, Lithuania, Netherlands
-
Ology BioservicesBaxter Innovations GmbHCompleted
-
Ology BioservicesBaxter Innovations GmbHCompleted
-
Ology BioservicesCompletedInfluenzaSingapore, Austria
-
Ology BioservicesCompletedInfluenzaSingapore, Hong Kong
-
Ology BioservicesCompleted
-
Ology BioservicesCompleted